Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports.
Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback